PT  - JOURNAL ARTICLE
AU  - Klaus Tschaikowsky
AU  - J. Schmidt
AU  - M. Meisner
TI  - Modulation of Mouse Endotoxin Shock by Inhibition of Phosphatidylcholine-Specific Phospholipase C
DP  - 1998 May 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 800--804
VI  - 285
IP  - 2
4099  - http://jpet.aspetjournals.org/content/285/2/800.short
4100  - http://jpet.aspetjournals.org/content/285/2/800.full
SO  - J Pharmacol Exp Ther1998 May 01; 285
AB  - During Gram-negative bacterial infections, lipopolysaccharide (LPS) interacts with monocyte/macrophage receptors, resulting in a host defense response. Activation of intracellular signal transduction pathways implicating various protein kinase and phospholipases is crucial in activating the transcription of genes encoding proinflammatory cytokines and inducible nitric oxide synthase (iNOS). In this article, we demonstrate that in mouse, endotoxin shock activation of phosphatidylcholine-specific phospholipase C (PC-PLC) plays a major role in controlling the inflammatory response. Inhibition of PC-PLC by the specific inhibitor tricyclodecan-9-yl-xanthogenate (D609) before LPS reduced the release of interleukin-1β, interleukin-6 and nitric oxide (NO) in vivo. In contrast, tumor necrosis factor-α serum levels were not altered by the pretreatment with D609. Consequently, survival from endotoxin shock of D609-treated animals was significantly improved compared with control animals (45% vs. 20%). Thus, inhibition of PC-PLC can reduce the inflammatory response to LPS and may serve as a novel approach to therapy of sepsis. The American Society for Pharmacology and Experimental Therapeutics